Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen
On August 4, Dianthus Therapeutics (NASDAQ:DNTH) reported second-quarter 2026 results alongside a stack of pipeline updates that touched nearly every program the company runs.
Dianthus Therapeutics Inc. (DNTH)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Avidity Partners Management David Witzke And Michael Gregory | 2,104,184 | $205,115,856 | 32.85% | |
| 2. | Octagon Capital Advisors Ting Jia | 1,841,667 | $179,525,699 | -6% | 16.14% |
| 3. | Deerfield Management James E. Flynn | 1,125,313 | $109,695,511 | +11% | 1.14% |
| 4. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,018,726 | $99,305,410 | -6% | 0.23% |
| 5. | Citadel Investment Group Ken Griffin | 974,911 | $95,034,324 | -40% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.63 | 24,670 | $336,252.10 | 1,928,503 | 2023-09-29 | Filing | |
| $13.15 | 30,000 | $394,500.00 | 1,903,833 | 2023-09-26 | Filing | |
| $13.20 | 2,000 | $26,400.00 | 4,000 | 2023-09-22 | Filing | |
| $13.20 | 2,000 | $26,400.00 | 2,000 | 2023-09-21 | Filing | |
| $13.20 | 30,000 | $396,000.00 | 1,873,833 | 2023-09-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $104.39 | 700 | $73,073.00 | 0 | 2026-09-17 | Filing | |
| $103.20 | 1,100 | $113,520.00 | 700 | 2026-09-17 | Filing | |
| $102.39 | 3,501 | $358,467.39 | 1,800 | 2026-09-17 | Filing | |
| $101.37 | 6,771 | $686,376.27 | 5,301 | 2026-09-17 | Filing | |
| $100.43 | 7,928 | $796,209.04 | 12,072 | 2026-09-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,199,893 | $799,325,570 | 0.03% | |
| 2. | 4,123,822 | $401,990,169 | 0.01% | |
| 3. | 3,229,882 | $314,848,897 | 0.05% | |
| 4. | 2,537,191 | $247,325,379 | 16.35% | |
| 5. | 2,357,440 | $229,798,634 | 0.01% |
News See All
10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds
In this article, we will take a look at some of the best mid-cap healthcare stocks that are being highly favored by hedge funds.
10 Best 52-Week High US Stocks to Buy
In this article, we will discuss the 10 Best 52-Week High US Stocks to Buy.
Top 10 Boring Stocks That Make Money
In this article, we will be taking a look at the Top 10 Boring Stocks That Make Money.
Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH)
Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 4, Guggenheim increased the price target on Dianthus Therapeutics Inc.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best fast money stocks to buy now. Clear Street assumed coverage on Dianthus Therapeutics, Inc.
11 Best Fast Money Stocks to Buy Now
In this article, we will take a look at some of the best fast money stocks to buy now. In this fast-paced world, most people have become impatient.
Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential
We recently published 10 Stocks With Eye-Popping Gains; 7 Soar to Fresh Highs. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is one of the top performers on Monday.
Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best small company stocks to invest in. Stifel reaffirmed a Buy rating on Dianthus Therapeutics, Inc.
Hedge Fund Resource Center